Enanta pharmaceuticals, inc. (ENTA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
Cash flows from operating activities
Net income

-6,005

13,443

9,191

7,036

4,145

26,011

27,420

20,288

12,555

11,693

36,508

-8,426

-5,392

-4,980

-1,802

-1,076

-1,645

26,189

5,812

2,418

28,753

42,009

-5,042

50,053

-5,203

-5,370

-4,443

-4,138

-3,749

21,957

Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense

4,978

5,098

4,512

4,164

4,707

5,843

4,110

4,025

3,590

4,120

3,210

3,102

3,492

3,267

2,510

2,470

2,382

1,992

1,797

1,584

1,429

1,028

795

776

752

359

286

239

257

281

Depreciation and amortization expense

915

904

891

885

802

680

661

657

613

587

564

552

528

493

455

434

433

339

204

165

141

129

110

88

79

75

73

61

48

39

Deferred income taxes

-1,881

657

-1,185

-1,153

118

-918

-495

-438

129

2,662

7,586

-3,803

-3,527

-1,910

-2,840

1,265

-1,101

382

-48

-788

377

11,487

-

-

-

-

-

-

-

-

Income tax benefit from stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-102

0

1,919

-

-

-

-

-

-

-

-

Premium paid on marketable securities

1,410

988

-

-

-

-

22

54

242

1

389

-17

533

324

388

-36

-5

171

979

442

1,452

169

178

1,351

48

425

-

-

-

-

Gain on sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

0

1

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

49

330

847

1,276

1,236

977

597

348

-22

-88

-138

-158

-218

-188

-207

-294

-448

-562

-593

-619

-561

-471

-484

-434

-567

-635

-565

-296

-197

-204

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

2

-

5

4

5

-

-

-

-

Change in fair value of warrant liability and Series 1 nonconvertible preferred stock

-

-

-

-

-

-

-100

0

0

41

-114

-17

-15

-13

-15

-16

75

-15

203

-15

-17

176

102

-65

-186

-17

164

-17

214

20

Other non-cash items

-

2

12

0

2

-39

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

-24,951

1,257

6,946

4,736

-30,255

2,681

9,943

13,213

20,940

12,495

3,103

-1,448

-1,458

-2,424

-1,137

974

-4,865

2,580

3,565

4,643

-69,545

74,902

1,325

-599

719

-529

-68

207

-13,664

13,284

Unbilled receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1,009

576

-943

-174

-332

-888

511

655

675

145

-197

213

225

-1,350

Prepaid expenses and other current assets

5,682

-1,146

-2,348

3,595

6,416

3,182

-4,950

4,499

830

539

-3,094

530

1,827

-4,941

1,031

542

-885

276

5,572

1,150

367

-409

-407

-454

698

-405

16

562

-257

-14

Operating lease, right-of-use assets

-791

-520

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-552

-179

152

-1,247

2,762

124

-129

881

694

-129

-2,084

2,029

1,978

-1,290

774

-483

1,011

149

-211

-820

1,784

-1,296

589

-506

964

-648

735

-151

-911

442

Accrued expenses

404

-5,989

1,794

2,697

661

598

693

2,089

1,555

-2,494

2,298

583

572

-10

-88

2,276

-480

150

-618

782

84

-475

17

518

599

-1,317

1,003

81

707

-2,076

Income taxes payable

-

-

0

0

-5,858

4,470

1,388

-5,380

-4,877

959

-

-

-

-

-1,206

-4,294

2,307

3,741

-1,030

-12,308

-2,359

16,896

-

-

-

-

-

-

-

-

Operating lease liabilities

-891

-593

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-51

46

-5

10

-115

-26

124

Other long-term liabilities

-897

-67

-136

31

149

247

288

40

237

-1

72

57

16

333

95

167

58

77

515

111

14

9

-186

16

16

14

-184

11

12

14

Sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,210

1,008

0

4,040

3,373

2,999

0

18

2,436

Net cash provided by operating activities

14,674

12,363

8,545

2,533

30,086

30,254

28,341

4,048

-7,578

4,409

57,306

-4,796

-3,002

3,145

-2,126

-2,112

10,054

29,993

-2,375

-14,203

98,861

-5,610

-4,932

35,112

-4,130

-5,871

-2,503

-5,922

10,033

9,045

Cash flows from investing activities
Purchase of marketable securities

54,423

117,461

195,930

81,670

152,166

119,546

114,027

79,355

45,011

54,710

65,149

34,949

77,602

73,671

41,939

65,929

49,939

34,622

40,721

19,751

127,679

8,153

12,655

61,178

14,351

10,221

15,635

54,547

32,565

13,141

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,995

31,187

46,390

28,325

20,466

13,226

21,342

34,243

27,700

8,221

5,200

6,380

17,030

13,215

Proceeds from maturities and sale of marketable securities

82,525

80,748

144,018

69,053

155,995

98,999

106,701

48,995

52,220

52,766

50,482

43,348

79,986

75,489

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

354

488

296

2,230

2,507

384

623

1,102

752

504

234

741

578

953

415

613

1,513

2,197

1,580

400

100

256

485

378

141

24

202

52

341

11

Net cash used in investing activities

27,748

-37,201

-52,208

-14,847

1,322

-20,931

-7,949

-31,462

6,457

-2,448

-14,901

7,658

1,806

865

-6,147

-31,427

-457

-5,632

4,098

8,174

-107,485

7,027

9,213

-27,313

17,248

1,349

-7,638

-48,219

-15,858

2,499

Cash flows from financing activities
Proceeds from exercise of stock options

4,716

2,306

709

512

4,466

1,161

1,052

2,985

1,771

436

813

208

9

49

81

284

499

162

162

224

245

95

39

369

557

89

122

22

350

65

Payments of initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,467

688

1,385

Income tax benefit from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-102

0

1,919

-

-

-

-

-

-

-

-

Payments for settlement of share-based awards

358

1,140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of capital lease obligations

-

-

22

22

21

21

20

20

20

19

19

18

18

18

18

17

17

16

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

4,358

1,166

687

490

257

1,140

1,033

2,965

-6

417

1,007

190

-211

31

61

1,968

530

146

159

122

245

2,014

44

474

557

89

122

-1,445

59,554

-1,320

Net increase (decrease) in cash, cash equivalents and restricted cash

46,780

-23,672

-42,976

-11,824

31,665

10,463

21,425

-24,449

-1,127

2,378

43,412

3,052

-1,407

4,041

-8,212

-31,571

10,127

24,507

1,882

-5,907

-8,379

3,431

4,325

8,273

13,675

-4,433

-10,019

-55,586

53,729

10,224

Supplemental disclosure of cash flow information:
Cash paid for income taxes

-

-

57

2,660

9,950

5

4,684

11,521

9,870

13

561

5

4

1,018

3,500

3,405

4

5,707

506

17,500

22,000

66

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing information:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,244

1,282

Initial public offering costs included in accounts payable or accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

840

626

Purchases of fixed assets included in accounts payable and accrued expenses

-107

216

162

-1,440

294

1,304

43

-43

0

111

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities arising from obtaining right-of-use assets

866

1,131

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-